#Ireland #Dublin #Jazz Pharmaceuticals #Modeyso #Thomas Riga

Jazz Pharmaceuticals Appoints Thomas Riga as Chief Business Officer

On January 1, 2026, Jazz Pharmaceuticals plc announced the appointment of Thomas Riga as its new Chief Business Officer. This strategic move comes as the company continues to strengthen its leadership team to drive corporate development and maintain its commitment to providing innovative treatments to patients in need.
Mr. Riga, who had previously served as Chief Operating and Commercial Officer at Chimerix Inc., joined Jazz following its acquisition of Chimerix in April 2025. His previous role included leading corporate strategy, which successfully facilitated the sale of Chimerix to Jazz Pharmaceuticals. He has played a critical role in navigating complex regulatory landscapes, particularly in the approval and launch of therapies for severe conditions affecting children and young adults, such as the H3K27M-mutant diffuse midline glioma.
With over 25 years of experience in the pharmaceutical sector, Mr. Riga has demonstrated excellence in various areas, including sales, marketing, and business development. His extensive background includes multiple C-suite roles across recognized organizations, showcasing his readiness to take Jazz Pharmaceuticals forward in its mission to deliver revolutionary medications.
Renee Gala, the President and CEO of Jazz Pharmaceuticals, expressed enthusiasm for Mr. Riga's appointment.